Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 76Gynecologic 4Tumor-Agnostic 2Genitourinary 2Gastrointestinal 2Endocrine 2Other 1NET 1Head & Neck 1

Conditions

Tuberous Sclerosis 1Neuroendocrine Tumors 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

lutetium Lu 177 dotatate 28Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4Capecitabine 4olaparib 3copper dotatate CU-64 3atezolizumab 3Temozolomide 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
exemestane × NET × 1 year × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡